Whole Exome Sequencing Market Growth 2022: Key Players, Market size, challenges, and opportunities

The global whole exome sequencing market is growing at a rapid pace. Market growth attributes to the rising usage of exome in the identification and determination of genetic variants, increasing the chances of such diseases as Miller syndrome and Alzheimer's. Besides, the decreasing

The global whole exome sequencing market is growing at a rapid pace. Market growth attributes to the rising usage of exome in the identification and determination of genetic variants, increasing the chances of such diseases as Miller syndrome and Alzheimer's. Besides, the decreasing cost of sequencing and the use of whole-exome sequencing technology for varied applications, drive the market growth.

Furthermore, increasing product launch and regulatory approvals escalate the growth of the market. According to Market Research Future (MRFR), the global   is expected to reach USD 2,696.03 MN by 2025, growing at 19.80% CAGR throughout the forecast period (2019 – 2025). Advantages of whole-exome sequencing procedures increase the market size.

Major Players

Players leading the global Whole Exome Sequencing Market Growth include

  • BGI (China),
  • Illumina Inc. (US),
  • Eurofins Scientific (Belgium),
  • Agilent Technologies, Inc. (US),
  • Thermo Fisher Scientific (US),
  • Hoffmann-La Roche Ltd (Switzerland),
  • Ambry Genetics (US),
  • GENEWIZ (US),
  • Macrogen, Inc. (South Korea), and
  • Integragen SA (France),

Whole Exome Sequencing Market - Regional Analysis

North America dominates in the global whole exome sequencing price . The largest market share attributes to the high prevalence rate of cancer other chronic disorders and high healthcare expenditures. Besides, favorable government initiatives for the development and adoption of whole-exome sequencing technologies drive the growth of the regional market. Furthermore, efforts of private organizations aim to produce genome data for researchers and precision medicine research platforms foster regional market growth.

In addition, the presence of global players and encouragement research and development in healthcare boost regional market growth. Other factors, such as increased uptake of advanced technologies and high healthcare expenditures, substantiate the growth of the regional market. The US, backed by the rising demands for whole exome sequencing procedures, accounts for the significant growth contributor to the regional market.

Europe stands second in the global whole exome sequencing market. The market is driven by rising cancer cases and increasing programs to promote the adoption of genome sequencing. Moreover, recent advancements in the technology and the augmenting uptake of the advanced technology in the region foster the regional market.

In addition, the presence of a well-developed medical device industry and rising healthcare expenditure facilitates regional market growth. Also, factors such as the rising support and funding from public private sectors for research development fuel the market growth in the region.

The Asia Pacific whole exome sequencing market is emerging as the rapidly growing market, globally. Factors such as the increasing technological advancements, per capita income, and government initiatives to improve healthcare quality, drive the regional market growth.

Furthermore, the growing patient pool and the older population in China, India, and Australia have enabled the regional market to grow promisingly. Also, the rising demand for these whole exome sequencing procedures and the increasing adoption of advanced techniques in these procedures drive the regional market growth.

Whole Exome Sequencing Market - Segments

The report is segmented into five dynamics.

  • By Product: Kits (DNA Fragmentation, End Repair, A-Tailing, And Size Selection Kits, Library Preparation, Target Enrichment, others), Sequencer, Services {Sequencing Services, Data Analysis (Bioinformatics), others}, and others.
  • By Technology: Sequencing by Synthesis (SBS), ION Semiconductor Sequencing, and others.
  • By Application : Diagnostics {Cancer Diagnostics, Monogenic (Mendelian) Disorders, Monogenic Types of Diabetes, Movement Disorders, HIV, others}, Drug Discovery Development, Agriculture Animal Research, and others.
  • By End User: Research Centers Government Institutes, Hospitals Diagnostics Centers, Pharmaceutical Biotechnology Companies, and others.
  • By Regions: North America, Europe, APAC, and Rest of the World.

Global Whole Exome Sequencing Market - Competitive Analysis

Highly competitive, the whole exome sequencing market appears fragmented due to the presence of many well-established players. These players adopt strategic approaches such as mergers acquisitions, collaboration, expansion, and technology launch to strengthen their market positions.

They significantly invest in developing new technologies and upgrade their existing sequencing techniques. Also, they make substantial investments to expand their global footprints.

Table of Contents:

1 EXECUTIVE SUMMARY

1.1 OVERVIEW 17

1.1.1 MARKET SYNOPSIS 17

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 18

2.2 RESEARCH OBJECTIVE 18

2.3 LIST OF ASSUMPTIONS 19

3 RESEARCH METHODOLOGY

3.1 OVERVIEW 21

3.2 DATA MINING 21

3.3 SECONDARY RESEARCH 22

3.4 PRIMARY RESEARCH 23

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 24

3.5 FORECASTING TECHNIQUES 24

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25

3.6.1 BOTTOM-UP APPROACH 26

3.6.2 TOP-DOWN APPROACH 27

3.7 DATA TRIANGULATION 28

3.8 VALIDATION 28

TOC will be continue..

Industry/Innovations/Related News:

  • July 22, 2020 ---- Swift Biosciences, Inc.(the US), a leader in the commercialization of DNA RNA library preparation kits for Next-Generation Sequencing (NGS), announced its partnership with Otogenetics Corporation, a high throughput NGS clinical lab to distribute its Swift 2S® Turbo DNA Library Kits. Otogenetics offers prenatal testing, hereditary cancer risk assessment, deafness testing, rare diseases, clinical exome, and other tests for personalized medicine clinical trials.
  • The collaboration would help Otogenetics ramp its legacy disease personalized medicine service areas and initiatives by supercharging its clinical whole-exome sequencing (WES) offerings. The sequencing of exome allows researchers and clinicians to obtain decisions-making data for genetic variants responsible for Mendelian.

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5th Floor, New York,

New York 10013

 

 

 


shweta shweta

69 Blog posts

Comments